DNA Report Page 6
ethics approval Ethical approval was obtained from local research and ethics committee at the Royal Marsden Hospital (CCR ref: 3171).
provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Suzanne Carreira http://orcid.org/0000-0002-5077-5379
8 Toor SM, Syed Khaja AS, Alkurd I, et al. In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clin Exp Immunol 2018;191:189–97.
9 Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015;3:436–43.
10 Nowak A, Kok P, Lesterhuis W, et al. OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result. Journal of Thoracic Oncology 2018;13:S338–9.
11 Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 2017;171:934–49.
12 O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019;16:151–67.
13 Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients. JCI Insight 2018;3.
14 Gettinger S, Horn L, Jackman D, et al. Five-Year follow-up of nivolumab in previously treated advanced Non–Small-Cell lung cancer: results from the CA209-003 study. JCO 2018;36:1675–84.
15 Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 2018;8:1548–65.
16 Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017;168:707–23.
17 Sarter K, Leimgruber E, Gobet F, et al. Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes. J Exp Med 2016;213:177–87.
18 Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open- label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019;20:239–53.
19 Bernard-Tessier A, Baldini C, Martin P, et al. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer 2018;101:160–4.
Baas P, Fennell D, Kerr KM, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26:v31–9.
Scherpereel A, Wallyn F, Albelda SM, et al. Novel therapies for malignant pleural mesothelioma. Lancet Oncol 2018;19:e161–72. Dozier J, Zheng H, Adusumilli PS. Immunotherapy for malignant pleural mesothelioma: current status and future directions. Transl. Lung Cancer Res. 2017;6:315–24.
Yap TA, Aerts JG, Popat S, et al. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 2017;17:475–88.
Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open- label, phase 1B trial. Lancet Oncol 2017;18:623–30.
Chen DS, Mellman I. Elements of cancer immunity and the cancer– immune set point. Nature 2017;541:321–30.
Yi JS, Cox MA, Zajac AJ. T-Cell exhaustion: characteristics, causes and conversion. Immunology 2010;129:474–81.